Anthem Biosciences Ltd. Company History and Annual Growth Details

Our Company was originally incorporated as “Anthem Biosciences Private Limited” under the provisions of the Companies Act, 1956, pursuant to a certificate of incorporation dated June 13, 2006, issued by RoC. Subsequently, our Company was converted from a private company to a public company, pursuant to a board resolution dated October 18, 2024 and a resolution passed in the extraordinary general meeting of our Shareholders held on October 18, 2024 following which the name of our Company was changed to “Anthem Biosciences Limited” and a certificate of incorporation consequent upon conversion to public limited company was issued by the RoC on December 10, 2024.

2006

- Incorporation of our Company.

2007

- Commenced operations of our Company at Unit I and set up a custom synthesis plant with a capacity of 6 KL.

2008

- Commencement of the discovery biology services with a fermentation capacity of 2 KL.

2010

- Expanded the custom synthesis plant set up at Unit I increasing its capacity from 6 KL to 24 KL.

2013

- Received the first USFDA audit approval for Unit I.

2016

- Set up a high potent lab at Unit I - Bommasandra Facility.

2017

- Our Company, pursuant to an order dated November 30, 2017, amalgamated with Anthem Cellutions (India) Private Limited by way of an acquisition of 100% of its share capital.

- Set up a solid phase peptide synthesis GMP lab with a capacity of 6 KL at Unit 1.

- Commenced operations of our Company at Unit II and set up an automated GMP compliant custom synthesis plant with a capacity of 128 KL and a fermentation plant with a capacity of 80 KL.

- Received the second USFDA audit approval for Unit I.

2018

- Anthem Cellutions (India) Private Limited amalgamated into our Company.

2019

- Received the third USFDA approval for Unit I.

- Set up a flow chemistry lab at Unit I.

2020

- Commenced operations in biological facility 2 earmarked for a specific client.

2022

- Expanded the custom synthesis plant set up at Unit II increasing its capacity to 246 KL.

2023

- Received the first USFDA audit approval and first therapeutic goods administration audit for Unit II.

- Addition of Oligonucleotide lab in Unit I.

- Set a cGMP scale continuous flow manufacturing facility for Unit II.

2024

- Received the:

• second USFDA audit approval for Unit II;

• first ANVISA audit approval for Unit I(1); and

• first ANVISA audit approval for Unit II(1).

- Commenced operations of Neoanthem Lifesciences Private Limited, at Unit III designed as a chemistry lab and customer synthesis pilot plant for development, technology transfer and scale-up projects.

- Fermentation capacity expanded to 140 KL at Unit II.

- Conversion of our Company into a public limited company, under the name “Anthem Biosciences Limited”.

2025

- Received the fourth USFDA approval for Unit I.